Stockscreener 앱 받기
0.6503
11.52%
-0.0847
Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat
Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - WV News
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com Canada
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - WV News
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo
Axsome Therapeutics stock reaches all-time high of 152.94 USD By Investing.com - Investing.com Australia
Axsome Therapeutics stock reaches all-time high of 152.94 USD - Investing.com India
Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo
Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo
Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo
Axsome Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan
Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo
Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo
Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics stock hits all-time high at 144.19 USD - Investing.com India
Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks
[10-Q] AVENUE THERAPEUTICS, INC. Quarterly Earnings Report | ATXI SEC FilingForm 10-Q - Stock Titan
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo
Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo
Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN
Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma
Axsome Therapeutics Buys Global Rights To AZD7325 To Expand Epilepsy Pipeline - Pulse 2.0
Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail
Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com Australia
Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com India
Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa
0.56%
1.23%
자본화:
|
볼륨(24시간):